Jump to content
IGNORED

Covid-19: Razvoj vakcine, imunitet i primena medikamenata


beyoncé

Recommended Posts

1 hour ago, Kelt said:

nije covid, ali.. u Nature je izasao rad koji je za uzorak imao longitudinalnu studiju zaposlenih u americkoj vojsci, koji su praceni nekoliko decenija, i pokazalo se da svi koji su oboleli od multiple skleroze u preko 70% slucajeva su imali infekciju Epstein Barr virusom, i sada je Moderna zapocela studiju sa mRNA vakcinom za Epstein-Barr..

 

fakticki su dokazali da je uzrocnik MS EB virus, a zahvaljujuci tome sto su imali koherentnu grupu ispitanika (gde naci ljude na istom mestu posle 20-30 godina sem u vojsci ili zatvoru)

Hmmm. Moj kolega je ovo imao dva puta. Kako je moguce?

Link to comment
  • 2 weeks later...

  

Quote

Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

The study will evaluate up to 1,420 participants across the three cohorts:

Cohort #1 (n = 615): Received two doses of the current Pfizer-BioNTech COVID-19 vaccine 90-180 days prior to enrollment; in the study, participants will receive one or two doses of the Omicron-based vaccine
Cohort #2 (n = 600): Received three doses of the current Pfizer-BioNTech COVID-19 vaccine 90-180 days prior to enrollment; in the study, participants will receive one dose of the current Pfizer-BioNTech COVID-19 vaccine or the Omicron-based vaccine
Cohort #3 (n=205): Vaccine-naïve participants will receive three doses of the Omicron-based vaccine

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based

Link to comment
On 15.1.2022. at 23:31, Kelt said:

nije covid, ali.. u Nature je izasao rad koji je za uzorak imao longitudinalnu studiju zaposlenih u americkoj vojsci, koji su praceni nekoliko decenija, i pokazalo se da svi koji su oboleli od multiple skleroze u preko 70% slucajeva su imali infekciju Epstein Barr virusom, i sada je Moderna zapocela studiju sa mRNA vakcinom za Epstein-Barr..

 

fakticki su dokazali da je uzrocnik MS EB virus, a zahvaljujuci tome sto su imali koherentnu grupu ispitanika (gde naci ljude na istom mestu posle 20-30 godina sem u vojsci ili zatvoru)

Nešto mi nije jasno. Evo sta CDC kaze o tom virusu:

"It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives. "

I ako se vecina ljudi zarazi tim virusom u toku života, kako je onda značajan rezultat reci da je 70% obolelih od MS imalo EBV? Koliki je procenat onih koji nisu oboleli od MS koji su takodje imali ovaj čest virus?

Link to comment
  • 2 weeks later...

Modernina novorazvijena vakcina protiv omikrona kao buster posle 2 dosadašnje ne daje ništa bolje rezultate od uzimanja trećeg uzimanja dosadašnje Modernine vakcine, pokazuju prvi rezultati na makaki majmunima.

 

 

Link to comment

Je l' realno da su toliki kreteni!?
Pandemija nas ukanalila sve, na milion razlicitih nacina, razbija nas i dalje, agonija traje godinama, a kreteni ne dele znanje jedni s drugima, ne saradjuju..
Umesto da se ujedine i da se resi ovo vise, oni se zajebavaju.
Pa jebem im mater.

A onda s druge strane.. - "Vakcinisite se, potrebno je, vazno je."

Pa ako je potrebno i vazno, jebeno saradjujte.. idioti.
 

Link to comment

Ja dobio ovo i pio.
Doktorka mi rekla sve ovo uglavnom.
Osnovno što mi je rekla da prepisuje "ako je rano uhvaćen virus".
Posle 3- 5 dana upitna efikasnost.







... Shiit has hit the fan

Link to comment

I kineska (još neodobrena) iRNK vakcina muči se s omikronom posle dve doze, a vakcine-kandidati napravljeni specijalno za omikron nisu praktično ništa bolji. Srećom, posle treće doze situacija je zadovoljavajuća.

 

 

 

Quote

In a lab study analysing samples from 11 vaccinated people, eight demonstrated "low but detectable" neutralization activity against Omicron, researchers said in a letter to editors published in the journal Cell Research.

The neutralising antibody level against Omicron showed a 47-fold reduction compared with the level against a "wild-type" that contains no major mutations, said the paper published on Monday.

But in animal tests, a third dose, given about nine months after the second shot, readily induced the production of neutralizing antibodies against Omicron and a wild-type strain, it said.

"Our data presented here clearly demonstrate that a third dose of ARCoV would probably lead to a sharp increase in neutralization antibodies not only against the WT (wild type) SARS-CoV-2 but also the newly Omicron variant," the study said.

The researchers said they also conducted animal tests on two new mRNA vaccine candidates targeting Omicron and the result showed that the induced antibody levels were comparable to those elicited by the original ARCoV.


https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-potential-mrna-covid-vaccine-weaker-against-omicron-study-2022-02-15/?taid=620bc37a00a90b00013654f4&utm_campaign=trueanthem&utm_medium=trueanthem&utm_source=twitter

Edited by vememah
Link to comment

Još jedna inekcija. Booring.

Kad će konačno neka inhalaciona vakcina da dobije upotrebnu dozvolu. Pored mnogo lakšeg primanja, povećava mogućnost sterilišućeg imuniteta, koji bi sprečio širenja, kao i stvaranja antitela i u disajnim putevima, da se virus zaustavi i pre nego dodje do sa krvi povezanim ćelijama pluća.

Znam da ima nekoliko zapadnih igrača, a evo vidim i kinezi su se uključili u igru.
https://www.biospace.com/article/releases/latest-study-shows-encouraging-results-of-cansinobio-s-inhaled-covid-19-vaccine-as-heterologous-booster/

Link to comment

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...